BACKGROUND

- Atopic dermatitis (AD) is a chronic inflammatory skin condition with a significant impact on patient quality of life (QoL) and requires long-term multidisciplinary clinical management.

- Considering the evolving treatment landscape in AD, it is important to understand real-world disease severity, and patient health care professional (HCP) and patient treatment goals and expectations.

OBJECTIVES

- To assess the clinical characteristics and disease severity in patients with a history of moderate-to-severe AD stratified by current treatments.

- To understand the rates of HCP and patient dissatisfaction with current disease control in patients with a history of moderate-to-severe AD.

KEY RESULTS

- Despite extended mean treatment duration (MTD), HCPs reported current moderate-to-severe disease severity in 50% of patients on systemics only (MTD=456 days), 64% on systemics + topicals (MTD=496 days), and 61% on topicals only (MTD=268 days).

- A higher proportion of patients were dissatisfied with the current level of disease control when topical therapies alone were prescribed.

CONCLUSIONS

- These descriptive results suggest that many patients treated with currently available systemics and topicals still have moderate-to-severe AD.

- A higher proportion of patients were dissatisfied with the current level of disease control when topical therapies alone were prescribed.

- Both patients and HCPs report dissatisfaction with disease control most often associated with lack of skin clear, unresolved flaring, and pruritus.

LIMITATIONS

- Physicians were requested to capture patient information retrospectively within the patient record forms, which may introduce recall bias – a common limitation of survey data.

- Judgments on reasons for dissatisfaction may have been based on a small sample size.

DISCLOSURES

- Dr. Lio has received consulting fees, speaker's honoraria, and grants from Lilly, Almirall, Mylan, Sobi, Janssen, Abbvie, and others. He has served as a consultant, advisor, or speaker for Mission Pharmaceuticals, Galderma, MSD, Regeneron, GSK, Janssen, and others. He has received honoraria and other compensation from others.

- Other signatories: Dr. Golant has received consulting fees, speaker's honoraria, and grants from Lilly, Almirall, Mylan, Sobi, Janssen, Abbvie, and others. He has served as a consultant, advisor, or speaker for Mission Pharmaceuticals, Galderma, MSD, Regeneron, GSK, Janssen, and others. He has received honoraria and other compensation from others.

- Dr. DeLuca has served as a consultant, advisor, or speaker for Mission Pharmaceuticals, Galderma, MSD, Regeneron, GSK, Janssen, and others. He has received honoraria and other compensation from others.

- Dr. Myers reports consulting/advisory boards for Abbvie, Almirall, Mylan, Sobi, Janssen, and others, as well as honoraria for Galderma, MSD, Regeneron, and others. She has served as a consultant, advisor, or speaker for Mission Pharmaceuticals, Galderma, MSD, Regeneron, GSK, Janssen, and others. She has received honoraria and other compensation from others.

- Dr. Geng has served as a consultant, advisor, or speaker for Lilly, RAPT, Sanofi, Regeneron, and others. He has received honoraria and other compensation from others.

- Dr. Lio has a patent on the speaker's bureau for Abbvie, Almirall, QiLi and Company (Lilly), Galderma, Genentech, GSK, Incyte, LEO Pharma, and others. He has served as an advisor, consultant, speaker, and/or investigator for Abbvie, Almirall, Regeneron, Sibel Health, Sereno Suisse Technologies, and others. Dr. Lio has received honoraria and other compensation from others.

- Dr. Golant has served as an advisor, consultant, speaker, and/or investigator for Mission Pharmaceuticals, Galderma, MSD, Regeneron, and others. He has received honoraria and other compensation from others.

- Dr. DeLuca has served as a consultant, advisor, or speaker for Mission Pharmaceuticals, Galderma, MSD, Regeneron, GSK, Janssen, and others. She has received honoraria and other compensation from others.